Novartis Vaccines

The strength of a global healthcare company

Novartis Vaccines, the maker of Menveo®, is the world’s fifth-largest vaccines manufacturer, the second-largest supplier of influenza vaccines in the United States, and is creating innovative solutions to combat deadly diseases globally. In fact, every 25 seconds, someone in the world receives a Novartis vaccine.

Creating a community of wellness

At Novartis Vaccines, we believe that caring for patients begins with helping to protect individuals and societies from infection—and that the only thing better than finding a cure for a disease is preventing illness in the first place.

Dedicated to preventing meningococcal disease

Now we’ve put our energy and resources together to protect patients against this terrible disease. The result is Menveo, a meningococcal vaccine. Menveo has been shown to be safe and effective in preventing meningococcal disease, plus it requires only 1 dose at time of vaccination.1

Indication

Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menveo is approved for use in persons 2 to 55 years of age. Menveo does not prevent N. meningitidis serogroup B infections.

Important Safety Information

You should not receive Menveo if you have had a severe allergic reaction to any ingredient of the vaccine, or if you have had a severe allergic reaction to a vaccine containing similar components as Menveo.

Side effects to Menveo include pain at the injection site, headache, muscle pain, fatigue, nausea, and fainting. Sometimes fainting is accompanied by falling with injury. Other side effects may occur.

Following vaccination with another US-licensed meningococcal conjugate vaccine, an evaluation of postmarketing adverse events suggested a potential for increased risk of Guillain-Barré Syndrome (GBS). There is not enough information to evaluate if a risk of GBS exists following administration of Menveo.

Tell your doctor if you are pregnant or planning to get pregnant.

Vaccination with Menveo may not protect all individuals.

For more information about Menveo, talk to your health-care professional.

Menveo.com has been developed by Novartis Vaccines as part of the company’s commitment to individual and public health.

Reference

  1. Menveo [prescribing information]. Cambridge, MA: Novartis Vaccines and Diagnostics Inc; 2010.

Menveo.com Exit Notice

You are now leaving the Menveo.com site and moving to an external website independently operated and not managed by Novartis Vaccines and Diagnostics Inc. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel. Or, click OK to continue.

OKCancel